Pharmacokinetics of ibuprofen in patients with cystic fibrosis

Daryl J. Murry, Christopher M. Oermann, Ching Nan Ou, Cheryl Rognerud, Dan K. Seilheimer, Marianna M. Sockrider

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Study Objectives. To determine the pharmacokinetic disposition of high doses of ibuprofen in patients with cystic fibrosis (CF), and to evaluate the reliability of intrapatient dosage adjustments to achieve recommended peak ibuprofen plasma concentrations. Design. First-order absorption, one- compartment model was fit to serial ibuprofen concentration-time data obtained from patients with CF and receiving high doses of ibuprofen 20-30 mg/kg. Setting. Medical school-affiliated teaching hospital. Patients. Ninety-eight patients with CF (53 males, 45 females; mean age 12.5 yrs). Measurements and Main Results. The time to achieve apparent maximum ibuprofen concentration (T(max)) ranged from 1-3 hours, with maximum concentrations ranging from 21-150 μg/ml (mean 83 μg/ml). Apparent ibuprofen clearance (Cl/F) was significantly correlated with age (r2 = 0.43, p<0.0001) and measures of body size (body surface area [BSA] r2 = 0.50, p<0.0001). The Cl/F ranged from 21.1-114.7 ml/min/m2 (mean 45.5 ml/min/m2), a 5-fold difference. The Cl/F normalized to body weight decreased with increasing age (p=0.0009), but when normalized to BSA, there was no age-related change (p=0.65). Apparent volume of distribution was significantly correlated with age (r2 = 0.69, p<0.0001) and measures of body size (BSA r2 = 0.79, p<0.0001). Fourteen patients had ibuprofen dosage adjustments. The Cl/F was not different among doses; however, T(max) differed by an average of 1.25 hours (range 0-2 hrs). Conclusion. The substantial variability in ibuprofen disposition and clearance we report is greater than previously described. Individualized dosages and therapeutic drug monitoring may be required to ensure plasma concentrations considered necessary to prevent pulmonary deterioration in patients with CF.

Original languageEnglish (US)
Pages (from-to)340-345
Number of pages6
JournalPharmacotherapy
Volume19
Issue number3
DOIs
StatePublished - Jan 1 1999

Fingerprint

Ibuprofen
Cystic Fibrosis
Pharmacokinetics
Body Surface Area
Body Size
Drug Monitoring
Medical Schools
Teaching Hospitals
Body Weight
Lung

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Murry, D. J., Oermann, C. M., Ou, C. N., Rognerud, C., Seilheimer, D. K., & Sockrider, M. M. (1999). Pharmacokinetics of ibuprofen in patients with cystic fibrosis. Pharmacotherapy, 19(3), 340-345. https://doi.org/10.1592/phco.19.4.340.30944

Pharmacokinetics of ibuprofen in patients with cystic fibrosis. / Murry, Daryl J.; Oermann, Christopher M.; Ou, Ching Nan; Rognerud, Cheryl; Seilheimer, Dan K.; Sockrider, Marianna M.

In: Pharmacotherapy, Vol. 19, No. 3, 01.01.1999, p. 340-345.

Research output: Contribution to journalArticle

Murry, DJ, Oermann, CM, Ou, CN, Rognerud, C, Seilheimer, DK & Sockrider, MM 1999, 'Pharmacokinetics of ibuprofen in patients with cystic fibrosis', Pharmacotherapy, vol. 19, no. 3, pp. 340-345. https://doi.org/10.1592/phco.19.4.340.30944
Murry DJ, Oermann CM, Ou CN, Rognerud C, Seilheimer DK, Sockrider MM. Pharmacokinetics of ibuprofen in patients with cystic fibrosis. Pharmacotherapy. 1999 Jan 1;19(3):340-345. https://doi.org/10.1592/phco.19.4.340.30944
Murry, Daryl J. ; Oermann, Christopher M. ; Ou, Ching Nan ; Rognerud, Cheryl ; Seilheimer, Dan K. ; Sockrider, Marianna M. / Pharmacokinetics of ibuprofen in patients with cystic fibrosis. In: Pharmacotherapy. 1999 ; Vol. 19, No. 3. pp. 340-345.
@article{0751987102a94da58095f5d83d9267e8,
title = "Pharmacokinetics of ibuprofen in patients with cystic fibrosis",
abstract = "Study Objectives. To determine the pharmacokinetic disposition of high doses of ibuprofen in patients with cystic fibrosis (CF), and to evaluate the reliability of intrapatient dosage adjustments to achieve recommended peak ibuprofen plasma concentrations. Design. First-order absorption, one- compartment model was fit to serial ibuprofen concentration-time data obtained from patients with CF and receiving high doses of ibuprofen 20-30 mg/kg. Setting. Medical school-affiliated teaching hospital. Patients. Ninety-eight patients with CF (53 males, 45 females; mean age 12.5 yrs). Measurements and Main Results. The time to achieve apparent maximum ibuprofen concentration (T(max)) ranged from 1-3 hours, with maximum concentrations ranging from 21-150 μg/ml (mean 83 μg/ml). Apparent ibuprofen clearance (Cl/F) was significantly correlated with age (r2 = 0.43, p<0.0001) and measures of body size (body surface area [BSA] r2 = 0.50, p<0.0001). The Cl/F ranged from 21.1-114.7 ml/min/m2 (mean 45.5 ml/min/m2), a 5-fold difference. The Cl/F normalized to body weight decreased with increasing age (p=0.0009), but when normalized to BSA, there was no age-related change (p=0.65). Apparent volume of distribution was significantly correlated with age (r2 = 0.69, p<0.0001) and measures of body size (BSA r2 = 0.79, p<0.0001). Fourteen patients had ibuprofen dosage adjustments. The Cl/F was not different among doses; however, T(max) differed by an average of 1.25 hours (range 0-2 hrs). Conclusion. The substantial variability in ibuprofen disposition and clearance we report is greater than previously described. Individualized dosages and therapeutic drug monitoring may be required to ensure plasma concentrations considered necessary to prevent pulmonary deterioration in patients with CF.",
author = "Murry, {Daryl J.} and Oermann, {Christopher M.} and Ou, {Ching Nan} and Cheryl Rognerud and Seilheimer, {Dan K.} and Sockrider, {Marianna M.}",
year = "1999",
month = "1",
day = "1",
doi = "10.1592/phco.19.4.340.30944",
language = "English (US)",
volume = "19",
pages = "340--345",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "3",

}

TY - JOUR

T1 - Pharmacokinetics of ibuprofen in patients with cystic fibrosis

AU - Murry, Daryl J.

AU - Oermann, Christopher M.

AU - Ou, Ching Nan

AU - Rognerud, Cheryl

AU - Seilheimer, Dan K.

AU - Sockrider, Marianna M.

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Study Objectives. To determine the pharmacokinetic disposition of high doses of ibuprofen in patients with cystic fibrosis (CF), and to evaluate the reliability of intrapatient dosage adjustments to achieve recommended peak ibuprofen plasma concentrations. Design. First-order absorption, one- compartment model was fit to serial ibuprofen concentration-time data obtained from patients with CF and receiving high doses of ibuprofen 20-30 mg/kg. Setting. Medical school-affiliated teaching hospital. Patients. Ninety-eight patients with CF (53 males, 45 females; mean age 12.5 yrs). Measurements and Main Results. The time to achieve apparent maximum ibuprofen concentration (T(max)) ranged from 1-3 hours, with maximum concentrations ranging from 21-150 μg/ml (mean 83 μg/ml). Apparent ibuprofen clearance (Cl/F) was significantly correlated with age (r2 = 0.43, p<0.0001) and measures of body size (body surface area [BSA] r2 = 0.50, p<0.0001). The Cl/F ranged from 21.1-114.7 ml/min/m2 (mean 45.5 ml/min/m2), a 5-fold difference. The Cl/F normalized to body weight decreased with increasing age (p=0.0009), but when normalized to BSA, there was no age-related change (p=0.65). Apparent volume of distribution was significantly correlated with age (r2 = 0.69, p<0.0001) and measures of body size (BSA r2 = 0.79, p<0.0001). Fourteen patients had ibuprofen dosage adjustments. The Cl/F was not different among doses; however, T(max) differed by an average of 1.25 hours (range 0-2 hrs). Conclusion. The substantial variability in ibuprofen disposition and clearance we report is greater than previously described. Individualized dosages and therapeutic drug monitoring may be required to ensure plasma concentrations considered necessary to prevent pulmonary deterioration in patients with CF.

AB - Study Objectives. To determine the pharmacokinetic disposition of high doses of ibuprofen in patients with cystic fibrosis (CF), and to evaluate the reliability of intrapatient dosage adjustments to achieve recommended peak ibuprofen plasma concentrations. Design. First-order absorption, one- compartment model was fit to serial ibuprofen concentration-time data obtained from patients with CF and receiving high doses of ibuprofen 20-30 mg/kg. Setting. Medical school-affiliated teaching hospital. Patients. Ninety-eight patients with CF (53 males, 45 females; mean age 12.5 yrs). Measurements and Main Results. The time to achieve apparent maximum ibuprofen concentration (T(max)) ranged from 1-3 hours, with maximum concentrations ranging from 21-150 μg/ml (mean 83 μg/ml). Apparent ibuprofen clearance (Cl/F) was significantly correlated with age (r2 = 0.43, p<0.0001) and measures of body size (body surface area [BSA] r2 = 0.50, p<0.0001). The Cl/F ranged from 21.1-114.7 ml/min/m2 (mean 45.5 ml/min/m2), a 5-fold difference. The Cl/F normalized to body weight decreased with increasing age (p=0.0009), but when normalized to BSA, there was no age-related change (p=0.65). Apparent volume of distribution was significantly correlated with age (r2 = 0.69, p<0.0001) and measures of body size (BSA r2 = 0.79, p<0.0001). Fourteen patients had ibuprofen dosage adjustments. The Cl/F was not different among doses; however, T(max) differed by an average of 1.25 hours (range 0-2 hrs). Conclusion. The substantial variability in ibuprofen disposition and clearance we report is greater than previously described. Individualized dosages and therapeutic drug monitoring may be required to ensure plasma concentrations considered necessary to prevent pulmonary deterioration in patients with CF.

UR - http://www.scopus.com/inward/record.url?scp=0032980461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032980461&partnerID=8YFLogxK

U2 - 10.1592/phco.19.4.340.30944

DO - 10.1592/phco.19.4.340.30944

M3 - Article

C2 - 10221372

AN - SCOPUS:0032980461

VL - 19

SP - 340

EP - 345

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 3

ER -